A practical review of prognostic correlations of molecular biomarkers in glioblastoma

Molecular, histopathological, and genomic variants of glioblastoma

(2014) Michael Karsy   Frontiers in Bioscience-Landmark

Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes

(2014) M. Labussiere et al.   NEUROLOGY

Biological and clinical significance of the intratumour heterogeneity of PTEN protein expression and the corresponding molecular abnormalities of thePTENgene in glioblastomas

(2014) Miguel A. Idoate et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma

(2014) Michael Karsy et al.   TUMOR BIOLOGY

IDH1/IDH2but NotTP53Mutations Predict Prognosis in Bulgarian Glioblastoma Patients

(2014) Gergana Stancheva et al.   Biomed Research International

PDGFRAAmplification is Common in Pediatric and Adult High-Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma

(2013) Joanna J. Phillips et al.   BRAIN PATHOLOGY

Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations

(2013) C. Hartmann et al.   CLINICAL CANCER RESEARCH

IDH mutations in tumorigenesis and their potential role as novel therapeutic targets

(2013) Daniel Krell et al.   Future Oncology

Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy

(2013) Michael Weller et al.   INTERNATIONAL JOURNAL OF CANCER

Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients

(2013) Mohamad A. Salkeni et al.   JOURNAL OF NEURO-ONCOLOGY

Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution

(2013) Sandra H E Boots-Sprenger et al.   MODERN PATHOLOGY

Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma

(2013) R. C. Laxton et al.   NEURO-ONCOLOGY

Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis

(2013) Jiaxin Zhao et al.   NEURO-ONCOLOGY

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

(2013) Jason Beiko et al.   NEURO-ONCOLOGY

1p/19q testing has no significance in the workup of glioblastomas

(2013) K. H. Clark et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme

(2013) Bryant England et al.   TUMOR BIOLOGY

Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding

(2013) Arshawn Sami et al.   TUMOR BIOLOGY

Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance

(2012) T. E. Taylor et al.   CURRENT CANCER DRUG TARGETS

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas

(2012) Matthias Holdhoff et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era

(2012) Christine Carico et al.   PLoS One

Genetic profile of astrocytic and oligodendroglial gliomas

(2011) Hiroko Ohgaki et al.   Brain Tumor Pathology

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma

(2011) Qi SongTao et al.   CANCER SCIENCE

Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression

(2011) Nadia Malkoun et al.   JOURNAL OF NEURO-ONCOLOGY

US FDA perspective on challenges in co-developingin vitrocompanion diagnostics and targeted cancer therapeutics

(2011) Reena Philip et al.   Bioanalysis

PTEN Signaling pathways in glioblastoma

(2010) Dimpy Koul   CANCER BIOLOGY & THERAPY

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas

(2010) T. Ozawa et al.   GENES & DEVELOPMENT

Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma

(2010) Michael D. Blough et al.   JOURNAL OF NEURO-ONCOLOGY

Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome

(2009) Takuya Watanabe et al.   ACTA NEUROPATHOLOGICA

Worse Outcome in Primary Glioblastoma Multiforme With Concurrent Epidermal Growth Factor Receptor and p53 Alteration

(2009) Yolanda Ruano et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients

(2009) J. Felsberg et al.   CLINICAL CANCER RESEARCH

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations

(2009) Cameron Brennan et al.   PLoS One

p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation

(2008) Hongwu Zheng et al.   NATURE

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

(2007) Thierry Gorlia et al.   LANCET ONCOLOGY